2024

59. Sherry Qiu, Holly Rushmeier, and Kim R.M. Blenman. Towards Understanding the Impact of Guidance in Data Visualization Systems for Domain Experts. October 2024. IEEE VIS. [Corresponding Author]

58. Foldi J, Blenman KRM, Marczyk M, Gunasekharan V, Polanska A, Gee R, Davis M, Kahn AM, Silber A, Pusztai L. Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2024 Nov;208(2):369-377. doi: 10.1007/s10549-024-07426-3. Epub 2024 Jul 13. PMID: 39002068.

57. Amy Ly MD, Victor Garcia MD, Kim RM Blenman PhD, MS, Anna Ehinger MD, Katherine Elfer PhD MPH, Matthew G Hanna MD, Xiaoxian Li MD, Dieter JE Peeters MD PhD, Ryan Birmingham BS, Sarah Dudgeon MPH, Emma Gardecki BS, Rajarsi Gupta MD PhD, Jochen Lennerz MD PhD, Tony Pan PhD, Joel Saltz MD PhD, Keith A Wharton Jr MD PhD, Daniel Ehinger MD,  Balazs Acs MD PhD, Els Dequeker MD, Roberto Salgado MD, Brandon D Gallas PhD. Training pathologists to assess stromal tumor infiltrating lymphocytes in breast cancer synergizes efforts in clinical care and scientific research. Histopathology. 2024 May;84(6):915-923. doi: 10.1111/his.15140. PMID: 38433289.

56. Katherine Elfer, Emma Gardecki, Victor Garcia, Amy Ly, Evangelos Hytopoulos, Si, Wen, Matthew G Hanna, Dieter JE Peeters, Joel Saltz, Anna Ehinger, Sarah N., Dudgeon, Xiaoxian Li, Kim RM Blenman, Weijie Chen, Ursula Green, Ryan, Birmingham, Tony Pan, Jochen K. Lennerz, Roberto Salgado, Brandon D. Gallas. Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence Models. Mod Pathol. 2024 Apr;37(4):100439. doi: 10.1016/j.modpat.2024.PMID: 38286221.

55. Chowdhury Arif Jahangir, David B. Page, Glenn Broeckx, Claudia A. Gonzalez, Caoimbhe Burke, Clodagh Murphy, Jorge S Reis-Filho, Amy Ly, Paul W. Harms, Rajarsi R. Gupta, Michael Vieth, Akira I. Hida, Mohamed Kahila, Zuzana Kos, Paul J. van Diest, Sara Verbandt, Jeppe Thagaard, Reena Khiroya, Khalid Abduljabbar, Gabriela Acosta Haab, Balazs Acs, Sylvia Adams, Jonas S. Almeida, Isabel Alvarado-Cabrero, Farid Azmoudeh-Ardalan, Sunil Badve, Nurkhairul Bariyah Baharun, Enrique R. Bellolio, Vydehi Bheemaraju, Kim R.M. Blenman, Luciana Botinelly Mendonça Fujimoto, Octavio Burgues, Alexandros Chardas, Maggie Chon U Cheang, Francesco Ciompi, Lee A.D. Cooper, An Coosemans, Germán Corredor, Flavio Luis Dantas Portela, Frederik Deman, Sandra Demaria, Sarah N. Dudgeon, Mahmoud Elghazawy, Claudio Fernandez-Martín, Susan Fineberg, Stephen B. Fox, Jennifer M. Giltnane, Sacha Gnjatic, Paula I Gonzalez-Ericsson, Anita Grigoriadis, Niels Halama, Matthew G. Hanna, Aparna Harbhajanka, Steven N. Hart, Johan Hartman, Stephen Hewitt, Hugo M. Horlings, Zaheed Husain, Sheeba Irshad, Emiel A.M. Janssen, Tatsuki R. Kataoka, Kosuke Kawaguchi, Andrey I Khramtsov, Umay Kiraz, Pawan Kirtani, Liudmila L. Kodach, Konstanty Korski, Guray Akturk, Ely Scott, Anikó Kovács, Anne-Vibeke Laenkholm, Corinna Lang-Schwarz, Denis Larsimont, Jochen K. Lennerz, Marvin Lerousseau, Xiaoxian Li, Anant Madabhushi, Sai K. Maley, Vidya Manur Narasimhamurthy, Douglas K. Marks, Elizabeth S McDonald, Ravi Mehrotra, Stefan Michiels, Durga Kharidehal, Fayyaz ul Amir Afsar Minhas, Shachi Mittal, David A. Moore, Shamim Mushtaq, Hussain Nighat, Thomas Papathomas, Frederique Penault-Llorca1, Rashindrie D. Perera, Christopher J. Pinard, Juan Carlos Pinto-Cardenas, Giancarlo Pruneri, Lajos Pusztai, Nasir Mahmood Rajpoot, Bernardo Leon Rapoport, Tilman T. Rau, Joana M. Ribeiro, David Rimm, Anne-Vincent Salomon, Joel Saltz, Shahin Sayed, Evangelos Hytopoulos, Sarah Mahon, Kalliopi P. Siziopikou, Christos Sotiriou, Albrecht Stenzinger, Maher A. Sughayer, Daniel Sur, Fraser Symmans, Sunao Tanaka, Timothy Taxter, Sabine Tejpar, Jonas Teuwen, E. Aubrey Thompson, Trine Tramm, William T. Tran, Jeroen van der Laak, Gregory E. Verghese, Giuseppe Viale, Noorul Wahab, Thomas Walter, Yannick Waumans, Hannah Y Wen, Wentao Yang, Yinyin Yuan, John Bartlett, Sibylle Loibl, Carsten Denkert, Peter Savas, Sherene Loi, Elisabeth Specht Stovgaard, Roberto Salgado, William M. Gallagher, Arman Rahman. Image-Based Multiplex Immune Profiling of Cancer Tissues: Translational Implications. A Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. J Pathol. 2024 Mar;262(3):271-288. doi: 10.1002/path.6238. PMID: 38230434.

2023

54. Steven Hart, Victor Garcia, Sarah N Dudgeon, Matthew G Hanna, Xiaoxian Li, Kim RM Blenman, Katherine Elfer, Amy Ly, Roberto Salgado, Joel Saltz, Rajarsi Gupta, Evangelos Hytopoulos, Denis Larsimont, Jochen Lennerz, and Brandon D Gallas. Initial interactions with the FDA on developing a validation dataset as a medical device development tool. J Pathol. 2023 Dec;261(4):378-384. doi: 10.1002/path.6208. PMID: 37794720.

53. Kim R. M. Blenman, Rodney Hull, Charles Maimela, Thulo Molefi, Richard Khanyile, and Zodwa Dlamini. Society 5.0 Healthcare: Ethics, Legal Rights, Human Rights, Safety and Security. In: Dlamini, Z. (eds) Society 5.0 and Next Generation Healthcare. 2023. Springer, Cham. https://doi.org/10.1007/978-3-031-36461-7_12. [Corresponding Author]

52. Meshack N. Bida, Sylvia Motlalepule Mosito, Thabiso Victor Miya, Demetra Demetriou, Kim R. M. Blenman, and Zodwa Dlamini. Transformation of the Healthcare Ecosystem in the Era of Society 5.0. In: Dlamini, Z. (eds) Society 5.0 and Next Generation Healthcare. Springer, Cham. https://doi.org/10.1007/978-3-031-36461-7_10.

51. Botle Precious Damane, Mahlatse Cordelia Kgokolo, Guy Roger Gaudji, Kim R. M. Blenman, and Zodwa Dlamini. Integration of Cyber-Physical Systems in the Advancement of Society 5.0 Healthcare Management. In: Dlamini, Z. (eds) Society 5.0 and Next Generation Healthcare. Springer, Cham. https://doi.org/10.1007/978-3-031-36461-7_9.

50. Rodney Hull, Nkhensani Chauke-Malinga, Guy Roger Gaudji, Kim R. M. Blenman, and Zodwa Dlamini. The Role of Digital Twinning, the Next Generation of EMR/EHR in Healthcare in a Society 5.0: Collecting Patient Data from Birth to the Grave. In: Dlamini, Z. (eds) Society 5.0 and Next Generation Healthcare. Springer, Cham. https://doi.org/10.1007/978-3-031-36461-7_8.

49. Sikhumbuzo Z. Mbatha, Thanyani V. Mulaudzi, Zukile Mbita, Henry A. Adeola, Jyotsna Batra, Kim R. M. Blenman, and Zodwa Dlamini. Artificial Intelligence–Enhanced Drug Discovery and the Achievement of Next-Generation Human-Centered Health System. In: Dlamini, Z. (eds) Society 5.0 and Next Generation Healthcare. Springer, Cham. https://doi.org/10.1007/978-3-031-36461-7_7.

48. Rahaba Marima, Nompumelelo Mtshali, Pumza Phillips, Thulo Molefi, Richard Khanyile, Zukile Mbita, Mandisa Mbeje, Aristotelis Chatziioannou, Kim R. M. Blenman, and Zodwa Dlamini. Health Informatics Applications in Healthcare and Society 5.0. In: Dlamini, Z. (eds) Society 5.0 and Next Generation Healthcare. Springer, Cham. https://doi.org/10.1007/978-3-031-36461-7_2.

47. Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, Azmoudeh-Ardalan F, Badve S, Baharun NB, Balslev E, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Chon U Cheang M, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dahl AB, Dantas Portela FL, Deman F, Demaria S, Doré Hansen J, Dudgeon SN, Ebstrup T, Elghazawy M, Fernandez-Martín C, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hauberg S, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Roslind A, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Scott E, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Fineberg S, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Zin RM, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group. J Pathol. 2023 Aug;260(5):498-513. doi: 10.1002/path.6155. Epub 2023 Aug 23. PMID: 37608772.

46. Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Ely S, Fernandez-Martín C, Fineberg S, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hardas A, Hart SN, Hartman J, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Adams S, Bartlett JMS, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. J Pathol. 2023 Aug;260(5):514-532. doi: 10.1002/path.6165. Epub 2023 Aug 23. PMID: 37608771.

45. Akingbesote ND, Owusu D, Liu R, Cartmel B, Ferrucci LM, Zupa M, Lustberg MB, Sanft T, Blenman KRM, Irwin ML, Perry RJ. A review of the impact of energy balance on triple-negative breast cancer. J Natl Cancer Inst Monogr. 2023 May 4;2023(61):104-124. doi: 10.1093/jncimonographs/lgad011. PMID: 37139977.

44. Fanucci KA, Bai Y, Pelekanou V, Nahleh ZA, Shafi S, Burela S, Barlow WE, Sharma P, Thompson AM, Godwin AK, Rimm DL, Hortobagyi GN, Liu Y, Wang L, Wei W, Pusztai L, Blenman KRM. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. NPJ Breast Cancer. 2023 May 13;9(1):38. doi: 10.1038/s41523-023-00535-0. PMID: 37179362; PMCID: PMC10182981. [Corresponding Author]

2022

43. Kahn, A.M., Blenman, K.R.M., Sonis, S.T., Lustberg, M.B. Strategies to mitigate the toxicity of cancer therapeutics. 2022. Advances in Cancer Research. PMID: 35779875.

42. Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan NL, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. NPJ Breast Cancer. 2022 Nov 7;8(1):119. doi: 10.1038/s41523-022-00492-0. PMID: 36344517; PMCID: PMC9640562.

41. Rozenblit M*, Blenman K*, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Res Treat. 2022 Nov;196(1):221-227. doi: 10.1007/s10549-022-06712-2. Epub 2022 Aug 26. PMID: 36028784. [Co-First Author]

40. Wall I, Boulat V, Shah A, Blenman KRM, Wu Y, Alberts E, Calado DP, Salgado R, Grigoriadis A. Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood. Cancers (Basel). 2022 Sep 17;14(18):4505. doi: 10.3390/cancers14184505. PMID: 36139665; PMCID: PMC9496983.

39. Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clin Cancer Res. 2022 Sep 1;28(17):3720-3728. doi: 10.1158/1078-0432.CCR-22-0862. PMID: 35903931; PMCID: PMC9444984.

38. Michal Marczyk, Tao Qing, Tess O’Meara, Vesal Yaghoobi, Vasiliki Pelekanou, Yalai Bai, Eiman Ibrahim, Xiaotong Li, Vignesh Gunasekharan, Andrea Silber, David Rimm, Lajos Pusztai, and Kim RM Blenman. Tumor Immune Microenvironment of Self-Identified African American and Non-African American Triple Negative Breast Cancer. 2022 npj Breast Cancer. PMID: 35869114. [Co-Corresponding Author]

37. Elfer K, Dudgeon S, Garcia V, Blenman K, Hytopoulos E, Wen S, Li X, Ly A, Werness B, Sheth MS, Amgad M, Gupta R, Saltz J, Hanna MG, Ehinger A, Peeters D, Salgado R, Gallas BD. Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithms. J Med Imaging (Bellingham). 2022 Jul;9(4):047501. doi: 10.1117/1.JMI.9.4.047501. Epub 2022 Jul 27. PMID: 35911208; PMCID: PMC9326105.

36. Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jun 13;28(12):2587-2597. doi: 10.1158/1078-0432.CCR-21-3215. PMID: 35377948; PMCID: PMC9464605.

35. Hercules SM, Liu X, Bassey-Archibong BBI, Skeete DHA, Smith Connell S, Daramola A, Banjo AA, Ebughe G, Agan T, Ekanem IO, Udosen J, Obiorah C, Ojule AC, Misauno MA, Dauda AM, Egbujo EC, Hercules JC, Ansari A, Brain I, MacColl C, Xu Y, Jin Y, Chang S, Carpten JD, Bédard A, Pond GR, Blenman KRM, Manojlovic Z, Daniel JM. Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer. Cancer Causes Control. 2022 Jun;33(6):831-841. doi: 10.1007/s10552-022-01574-x. Epub 2022 Apr 6. PMID: 35384527; PMCID: PMC9085672.

34. Hercules SM, Alnajar M, Chen C, Mladjenovic SM, Shipeolu BA, Perkovic O, Pond GR, Mbuagbaw L, Blenman KR, Daniel JM. Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ Open. 2022 May 27;12(5): e055735. doi: 10.1136/bmjopen-2021-055735. PMID: 35623750; PMCID: PMC9150263.

33. Garcia V, Elfer K, Peeters DJE, Ehinger A, Werness B, Ly A, Li X, Hanna MG, Blenman KRM, Salgado R, Gallas BD. Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer. Cancers (Basel). 2022 May 17;14(10):2467. doi: 10.3390/cancers14102467. PMID: 35626070; PMCID: PMC9139395.

32. Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Res. 2022 May 3;82(9):1698-1711. doi: 10.1158/0008-5472.CAN-21-3983. PMID: 35247885.

31. Kahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. Adv Cancer Res. 2022; 155:215-244. doi: 10.1016/bs.acr.2022.02.006. Epub 2022 Mar 21. PMID: 35779875.

2021

30. Yaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O'Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study. Breast Cancer Res. 2021 Dec 14;23(1):113. doi: 10.1186/s13058-021-01493-w. PMID: 34906209; PMCID: PMC8670126.

29. El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group [Blenman, K]. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. PMID: 34853355; PMCID: PMC8636568.

28. Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature. 2021 Oct;598(7882):682-687. doi: 10.1038/s41586-021-03994-2. Epub 2021 Oct 20. PMID: 34671158; PMCID: PMC8555464.

27. Paula I. Gonzalez-Ericsson, Julia D. Wulfkuhle, Rosa I. Gallagher, Xiaopeng Sun, Margaret Axelrod, Henry L. Gomez, Violeta Sánchez, Melinda E. Sanders, Lajos Pusztai, Emanuel Petricoin, Kim R.M. Blenman, Justin M. Balko. Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in HER2-negative breast cancer. 2021. Clinical Cancer Research. PMID: 34315723. [Co-Corresponding Author]

26. Iwase T, Blenman KRM, Li X, Reisenbichler E, Seitz R, Hout D, Nielsen TJ, Schweitzer BL, Bailey DB, Shen Y, Zhang X, Pusztai L, Ueno NT. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers (Basel). 2021 Sep 28;13(19):4839. doi: 10.3390/cancers13194839. PMID: 34638323; PMCID: PMC8508147.

25. Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. Am J Clin Pathol. 2021 Jul 6;156(2):214-228. doi: 10.1093/ajcp/aqaa217. PMID: 33555016.

24. Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. NPJ Breast Cancer. 2021 Feb 8;7(1):9. doi: 10.1038/s41523-021-00219-7. Erratum in: NPJ Breast Cancer. 2022 Feb 3;8(1):17. PMID: 33558513; PMCID: PMC7870853.

23. Spidlen J, Moore W, Parks D, Goldberg M, Blenman K, Cavenaugh JS; ISAC Data Standards Task Force, Brinkman R. Data File Standard for Flow Cytometry, Version FCS 3.2. Cytometry A. 2021 Jan;99(1):100-102. doi: 10.1002/cyto.a.24225. Epub 2020 Sep 16. PMID: 32881398; PMCID: PMC8241566.

22. Blenman KRM, Spidlen J, Parks DR, Moore W, Treister A, Leif R, Bray C, Goldberg M; ISAC Data Standards Task Force, Brinkman R. ISAC Probe Tag Dictionary: Standardized Nomenclature for Detection and Visualization Labels Used in Cytometry and Microscopy Imaging. Cytometry A. 2021 Jan;99(1):103-106. doi: 10.1002/cyto.a.24224. Epub 2020 Sep 16. PMID: 32881392; PMCID: PMC8388112. [Corresponding Author]

2020

21. Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. 2020 Nov;8(2): e001558. doi: 10.1136/jitc-2020-001558. PMID: 33239417; PMCID: PMC7689582.

20. Ahmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, Rimm DL. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer. Clin Cancer Res. 2020 Oct 15;26(20):5456-5461. doi: 10.1158/1078-0432.CCR-20-1303. Epub 2020 Jul 24. PMID: 32709714; PMCID: PMC7572612.

19. O'Meara T, Marczyk M, Qing T, Yaghoobi V, Blenman K, Cole K, Pelekanou V, Rimm DL, Pusztai L. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers. JCO Precis Oncol. 2020 Jun 26;4:PO.19.00350. doi: 10.1200/PO.19.00350. PMID: 32923897; PMCID: PMC7446500.

18. Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group [Blenman, K]. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer. 2020 May 12; 6:15. doi: 10.1038/s41523-020-0155-1. PMID: 32436923; PMCID: PMC7217941.

17. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020 May 12; 6:17. doi: 10.1038/s41523-020-0156-0. PMID: 32411819; PMCID: PMC7217863.

16. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez- Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020 May 12; 6:16. doi:10.1038/s41523-020-0154-2. PMID: 32411818; PMCID: PMC7217824.

2019

15. Blenman KRM, Wang J, Cowper S, Bosenberg M. Pathology of spontaneous and immunotherapy-induced tumor regression in a murine model of melanoma. Pigment Cell Melanoma Res. 2019 May;32(3):448-457. doi: 10.1111/pcmr.12769. Epub 2019 Feb 27. PMID: 30702217; PMCID: PMC6500596. [Corresponding Author]

14. Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clin Cancer Res. 2019 Apr 15;25(8):2442-2449. doi: 10.1158/1078-0432.CCR-18-2652. Epub 2019 Jan 7. PMID: 30617133; PMCID: PMC6467753.

13. Kim R.M. Blenman and Marcus W. Bosenberg. Immune cell and cell cluster phenotyping, quantitation, and visualization using in silico multiplexed images and tissue cytometry. Cytometry A, 2019. PMID: 30468565. [Corresponding Author]

a. Featured on the Cover of this Issue of the Journal: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ cyto.a.23536

2018

12. Blenman KRM, He TF, Frankel PH, Ruel NH, Schwartz EJ, Krag DN, Tan LK, Yim JH, Mortimer JE, Yuan Y, Lee PP. Sentinel lymph node B cells can predict disease-free survival in breast cancer patients. NPJ Breast Cancer. 2018 Aug 23; 4:28. doi: 10.1038/s41523-018-0081-7. PMID: 30155518; PMCID: PMC6107630.

2017

11. Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G, Kaech S, Blenman K, Bosenberg M. UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. Pigment Cell Melanoma Res. 2017 Jul;30(4):428-435. doi: 10.1111/pcmr.12591. Epub 2017 Jun 8. PMID: 28379630; PMCID: PMC5820096.

2015

10. Spidlen J, Moore W; ISAC Data Standards Task Force [Blenman, K], Brinkman RR. ISAC's Gating-ML 2.0 data exchange standard for gating description. Cytometry A. 2015 Jul;87(7):683-7. doi: 10.1002/cyto.a.22690. Epub 2015 May 14. PMID: 25976062; PMCID: PMC4874733.

9. Spidlen J, Bray C, ISAC Data Standards Task Force (Kim RM Blenman), Brinkman RR: ISAC's classification results file format. Cytometry A 2015, 87:86-88. PMID:25407887.

2014

8. Xu Y, Wu W, Chang EI, Chen D, Mu J, Lee PP, Blenman KR, Tu Z. A two-layer structure prediction framework for microscopy cell detection. Comput Med Imaging Graph. 2015 Apr; 41:29-36. doi: 10.1016/j.compmedimag.2014.07.001. Epub 2014 Jul 15. PMID: 25082065.

7. Riess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, San-Pedro Salcedo M, Engleman E, Lee PP, Malik R, Wakelee HA. Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacol Immunotoxicol. 2014 Apr;36(2):182-6. doi: 10.3109/08923973.2013.864671. Epub 2014 Feb 5. PMID: 24494587; PMCID: PMC6464638.

6. Kim RM Blenman and Peter P Lee. Quantitative and Spatial Image Analysis of Tumor and Draining Lymph Nodes Using Immunohistochemistry and High-Resolution Multispectral Imaging to Predict Metastasis. Molecular Diagnostics for Melanoma: Emerging technologies for marker validation (Part 7). Methods in Molecular Biology (eds. Magdalena Thurin & Francesco Marincola), published by Springer Press, USA. 1102: 601 – 621, 2014. PMID:24259001. [Corresponding Author]

2006 and earlier

5. Blenman KR, Duan B, Xu Z, Wan S, Atkinson MA, Flotte TR, Croker BP, Morel L. IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest. 2006 Nov;86(11):1136-48. doi: 10.1038/labinvest.3700468. Epub 2006 Aug 21. PMID: 16924244.

4. Blenman KR, Bahjat FR, Moldawer LL, Morel L. Aberrant signaling in the TNFalpha/TNF receptor 1 pathway of the NZM2410 lupus-prone mouse. Clin Immunol. 2004 Feb;110(2):124-33. doi: 10.1016/j.clim.2003.09.009. PMID: 15003809.

     a. Editorial: Shangkui Xie and Chandra Mohan. Divide and conquer – the power of congenic strains. Clinical        Immunology. 110 (2): 109 – 111, 2004.

3. Morel L, Blenman KR, Croker BP, Wakeland EK. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1787-92. doi: 10.1073/pnas.98.4.1787. Epub 2001 Jan 23. PMID: 11172029; PMCID: PMC29335.

2. Morel L, Croker BP, Blenman KR, Mohan C, Huang G, Gilkeson G, Wakeland EK. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6670-5. doi: 10.1073/pnas.97.12.6670. PMID: 10841565; PMCID: PMC18697.

1. Morel L, Yu Y, Blenman KR, Caldwell RA, Wakeland EK. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm Genome. 1996 May;7(5):335-9. doi: 10.1007/s003359900098. PMID: 8661718.

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%